OKYO Pharma insider share purchases

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, announced a series of insider share purchases by its directors and officers between July 21 and July 23, 2026. Chairman Gabriele Cerrone, through Panetta Partners Limited, purchased 25,000 shares at $1.40 per share, increasing his total holding to 10,851,416 shares (20.51% of issued capital). Chief Medical Officer Flavio Mantelli purchased 20,000 shares at $1.40 per share. Chief Development Officer and Director Gary S. Jacob purchased 3,500 shares at $1.40 per share. Non-Executive Director John Brancaccio purchased 5,000 shares at $1.48 per share. The company plans to initiate a global Phase 3 pivotal trial for urcosimod in the second half of 2026.